Regulatory requirements of the food and drug administration would preclude product claims based on observational research

Health Affairs

Volumn 31, Issue 10, 2012, Pages 2188-2192

  Griffin, Joseph P ^a   Godfrey, Bryant M ^a   Sherman, Rachel E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSENSUS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH PROMOTION; HUMAN; MEDICAL RESEARCH; METHODOLOGY; OBSERVATIONAL STUDY; PRESCRIPTION; PUBLIC HEALTH; SCIENCE;

COMPARATIVE EFFECTIVENESS RESEARCH; GOVERNMENT REGULATION; PRESCRIPTION DRUGS; QUALITATIVE RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871966670     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0958     Document Type: Article

References (21)

1. Dentzer S Communicating about comparative effectiveness research: a Health Affairs symposium on the issues. Health Aff (Millwood). 2012;31(10), 2183-87.
2. [1962] Food, Drug, and Cosmetic Act Amendments, S. Rep. No. 87-1744. p. 37.
3. [1962] Food, Drug, and Cosmetic Act Amendments, S. Rep. No. 87-1744. p. 36.
4. [21] US Code, sec. 355(d)(5).
5. [21] US Code, sec. 355(d).
6. [21] CFR, sec. 314.126.
7. [21] CFR, sec. 314.126(b)(2).
8. [21] US Code, secs. 502(a), (n), (q), and ®. The FDA has authority over labeling and advertising for prescription drugs intended for human use [secs. 352(a) and (n)]. The FDA also has authority over labeling for all devices [sec. 352(a)]. The agency's authority over device advertising extends to restricted devices [secs. 352(q) and ®].
9. Other device advertising is regulated by the Federal Trade Commission (FTC) (15 US Code, sec. 52). Federal Trade Commission. Memorandumof understanding between Federal Trade Commission and the Food and Drug Administration. Fed Regist. 1971;36(180), 18539.
10. [21] US Code, sec. 321(k).
11. [21] US Code, sec. 321(m).
12. Kordel v. United States, 335 U.S. 345 (1948).
13. [21] CFR, secs. 202.1(l), (2).
14. [21] CFR, secs. 314.50(c)(2), 601.2(a), and 814.20(b)(10).
15. [21] US Code, sec. 352(f)(1); 21 CFR, secs. 201.100(c)(1) and 801.109(c).
16. [21] US Code, secs. 502(n) and ®.
17. [21] CFR, sec. 202.1(l)(1).
18. [21] US Code, secs. 352(q)(1) and 321(n); 21 CFR, sec. 202.1(e)(5).
19. Kesselheim A, Avorn J. The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research. Health Aff (Millwood). 2012;31 (10):2200-05.
20. Fischer M, Avorn J. Academic detailing can play a key role in assessing and implementing comparative effectiveness research. Health Aff (Millwood). 2012;31 (10):2206-12.
21. Selby J, Fleurence R, Lauer M, Schneeweiss S. Reviewing hypothetical migraine studies using funding criteria from the Patient-Centered Outcomes Research Institute. Health Aff (Millwood). 2012; 31(10):2193-99.